Significant Ownership of Affinity Asset Advisors, LLC
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Affinity Asset Advisors, LLC focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Andrew Weinstein - Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer
- Manager location
- New York, NY
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Affinity Asset Advisors, LLC with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from Affinity Asset Advisors, LLC
Significant Ownership of Affinity Asset Advisors, LLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| IBIO | iBio, Inc. | Common Stock, par value $0.001 per share | 10% | $7,675,906 | +$2,392,350 | 3,489,048 | +45% | Affinity Asset Advisors, LLC | 31 Mar 2026 |
| NXTC | NextCure, Inc. | Common Stock, $0.001 par value per share | 10% | $4,375,018 | +$1,966,899 | 348,607 | +82% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| OVID | Ovid Therapeutics Inc. | Common Stock, par value $0.001 per share | 9.1% | $45,030,194 | +$10,040,596 | 15,635,484 | +29% | Affinity Asset Advisors, LLC | 31 Mar 2026 |
| VTYX | Ventyx Bioscience, Inc. | Common Stock, $0.0001 par value per share | 9% | $58,381,906 | +$21,744,625 | 6,465,041 | +59% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| STRO | Sutro Biopharma, Inc. | Common Stock, $0.001 par value per share | 8.8% | $8,444,817 | 748,382 | Affinity Asset Advisors, LLC | 22 Jan 2026 | ||
| KPTI | Karyopharm Therapeutics Inc. | Common Stock, $0.0001 par value per share | 8.6% | $12,870,974 | +$7,880,460 | 1,713,092 | +158% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| KPTI | Karyopharm Therapeutics Inc. | Common Stock, $0.0001 par value per share | 8.6% | $1,244,110 | 2,073,517 | Affinity Asset Advisors, LLC | 31 Mar 2026 | ||
| FBRX | Forte Biosciences, Inc. | Common Stock, par value $0.001 per share | 7.3% | 1,011,890 | Affinity Asset Advisors, LLC | 31 Mar 2026 | |||
| LXEO | Lexeo Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 7.1% | $51,813,451 | +$9,589,340 | 5,217,660 | +23% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| HLXC | Helix Acquisition Corp. III | Class A ordinary shares, par value $0.0001 per share | 7% | $12,700,000 | 1,250,000 | Affinity Asset Advisors, LLC | 31 Mar 2026 | ||
| FBRX | Forte Biosciences, Inc. | Common Stock, par value $0.001 per share | 6.7% | $22,251,791 | -$731,169 | 834,964 | -3.2% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| STRO | Sutro Biopharma, Inc. | Common stock, $0.001 par value per share | 6.5% | $26,642,467 | -$137,363,902 | 1,069,519 | -84% | Affinity Asset Advisors, LLC | 31 Mar 2026 |
| AVTX | Avalo Therapeutics, Inc. | Common Stock, $0.001 par value per share | 5.5% | $19,321,504 | +$4,175,816 | 1,340,840 | +28% | Affinity Asset Advisors, LLC | 31 Mar 2026 |
| VRCA | Verrica Pharmaceuticals Inc. | Common Stock, $0.0001 par value per share | 5.5% | $7,346,762 | 884,172 | 0% | Affinity Asset Advisors, LLC | 22 Jan 2026 | |
| INZY | Inozyme Pharma, Inc. | Common Stock, par value $0.0001 per share | 2.9% | $2,203,898 | 1,867,710 | Affinity Healthcare Fund, LP | 20 May 2025 |
Schedules 13D/G Reported by Affinity Asset Advisors, LLC:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.